SUMMARY Skin disinfection with povidine-iodine (PVP-I) is widely used in obstetrics. We evaluated the influence of PVP-I in mothers at delivery on the serum thyroid stimulating hormone concentrations of their infants at the time of screening for congenital hypothyroidism. The study covered 4745 infants who were either breast fed (3659, 77%) or bottle fed (1086, 23%); 3086 (65%) of them were born to mothers with no iodine overload (controls) and 1659 (35%) to mothers with iodine overload. Compared with the control group, the breast and bottle fed infants born to mothers with iodide overload had a shift of neonatal thyroid stimulating hormone concentration towards high values. The shift was maximal in the breast fed infants with a 25 to 30 fold increase in the recall rate at screening for congenital hypothyroidism (serum thyroid stimulating hormone >50 mU/l) while in the bottle fed infants, the recall rate was barely modified. In conclusion, the use of PVP-I in mothers at delivery induces a transient impairment of thyroid function in their infants, especially if breast fed. This situation is detrimental to screening for congenital hypothyroidism. Consequently PVP-I is not recommended in obstetrics.
widely used in obstetrics in epidural anaesthesia or caesarean section. This procedure results in iodide overload of the mother due to cutaneous absorption of iodine. 1 Iodide readily crosses the placenta2 and is actively concentrated in the mammary gland. 3 Consequently, newborn infants born to mothers treated with PVP-I are also exposed to iodine overload, especially if breast fed. 4 The thyroid gland of newborns is highly sensitive to the blocking effect of excess iodide on thyroid hormone synthesis, and a raised concentration of serum thyroid stimulating hormone is the most reliable index of impairment of thyroid function.5
The objective of the present work was to evaluate the influence of cutaneous application of PVP-I in mothers at delivery on the concentrations of thyroid stimulating hormone in their infants at the time of screening for congenital hypothyroidism. In order to appreciate the specific role of the iodine contained in breast milk, a comparative study was performed between breast and bottle fed infants.
Patients and methods
The study included 4745 (96%) of the 4923 infants born in our maternity ward during a two year period. Of the 178 infants who were not included in the study, three were omitted because they had permanent congenital hypothyroidism due to thyroid agenesis with an appreciably raised serum thyroid stimulating hormone concentration and a low thyroxine concentration at screening and diagnosis. One hundred and seventy five (45 full term and 130 premature infants) were omitted because they were neither breast nor bottle fed: they were severely ill and received total parenteral nutrition until at least the fifth day of life. None of these 175 infants had a serum thyroid stimulating hormone concentration >50 mU/l at the time of screening for congenital hypothyroidism.
The 4745 infants under study were investigated on the fifth day of life at the time of screening for congenital hypothyroidism. As shown in table 1 they were distributed in several groups on the basis of the 1207 In the latter, the whole abdominal wall was covered by three applications of PVP-I. The 10% solution of PVP-I used contained 10 mg of iodine/ml. All the newborn infants were submitted to systematic neonatal screening for congenital hypothyroidism; serum thyroid stimulating hormone concentration was used as the primary screening test. When thyroid stimulating hormone concentration was above 20 mU/l serum thyroxine was measured in a second step from the initial blood spot. The criteria used for recalling an infant under suspicion of congenital hypothyroidism were a serum thyroid stimulating hormone concentration of >50 mU/l or a thyroid stimulating hormone concentration between 20 and 50 mU/l associated with a serum thyroxine concentration of <64 nmol/l.6 Further investigation included clinical, biological, and radiological assessments, and when necessary the infants were scanned. Serum thyroid stimulating hormone and thyroxine were measured in duplicate by specific radioimmunoassay: at screening on blood spots dried on filter paper (the sensitivity was 40 mU/l for thyroid stimulating hormone and 13 nmol/l for thyroxine) and at recall on serum (the sensitivity was 0-4 mU/l for thyroid stimulating hormone and 13 nmol/l for thyroxine).7
Statistical analyses determined the frequency distribution of serum thyroid stimulating hormone concentrations in the whole infant population under study and compared this distribution in the different groujs. The frequency distributions were compared by X tests.
Results
The frequency distribution of serum thyroid stimulating hormone concentration in the 4745 infants studied is shown in fig 1 .. * w obviously iodine overload. We have previously reported that there was a two and 12 fold increase in the iodine content of breast milk after the use of PVP-I for epidural anaesthesia and caesarean section respectively (table 2) .4 The shift in bottle fed infants probably results from moderate fetal iodine overload occurring between skin disinfection with PVP-I and delivery because of a transfer of iodine across the placenta.
Chabrolle and Rossier have shown that the application of PVP-I directly on the skin of infants occasionally increases their serum thyroid stimulating hormone concentrations.8 Our results indicate that the same phenomenon occurs when PVP-I is used in the mother before delivery.
In our study, all infants with moderately or appreciably raised serum thyroid stimulating hormone concentrations at screening had normal thyroxine at screening and all further investigations were also normal. Consequently, the raised serum thyroid stimulating hormone indicates a very transient state of compensated or subclinical hypothyroidism which, most probably, will not affect the long term development of the infants.5 9 Our study, however, underlines the public health importance of these transient alterations. In the newborn population under study, the recall rate was 1% instead of 0.2% in our screening programme.10 In addition, there was a clear cut increase in the frequency of moderately raised thyroid stimulating hormone between 10 and 50 mU/l, which also indicates some impairment of thyroid function, although the infants were not recalled.
This high recall rate is detrimental to the screening programme and increases its cost because of the further investigations needed. It also appreciably increases the frequency of so called 'false positives' at screening; this is an unfavourable situation for a screening programme.'1 Finally, but of major importance, the high recall rate causes unnecessary psychological stress in many families. Long term effects of this recall on the mother-infant relationship have been well documented; these adverse effects 
